Article
Tissue microarray and survival analysis of 113 patients with gliomas
Tissue Microarray und Überlebensanalyse von 113 Gliom-Patienten
Search Medline for
Authors
Published: | May 8, 2006 |
---|
Outline
Text
Objective: Gliomas are heterogeneous tumors with an unpredictable clinical course. Identification of prognostic or predictive factors would help to optimize therapy. The aim of this study was to obtain a useful tool to evaluate the role of presumable prognostic factors like O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, p53 mutations and LOH1p.
Methods: Paraffin embedded tumor samples from 113 Patients including 37 astrocytomas, 52 mixed gliomas and 47 oligodendrogliomas were collected in order to establish a tissue microarray (TMA). Patients were treated between 1990 and 2003 at our department. Clinical data regarding survival rates and treatment regimens were assessed in a specifically developed data base. The TMA was used for immunohistochemical analyses of MGMT, p53, and LOH 1p FISH analysis. Results were compared to patient outcome.
Results: Staining for accumulated p53 was observed in 86/113 cases and correlated with a reduced progression-free survival time (PFS). Expression of the MGMT gene was found in 35/113 cases in correlation with an increased PFS and overall survival time (OS). LOH 1p was determined in 71/113 cases and was related to an improved PFS after treatment with BCNU.
Conclusions: We successfully generated a tissue microarray of more than 100 clinically well-defined gliomas, which allows the analysis of large series of tumor specimens under reproducible conditions. In the present study, both MGMT expression and LOH1p turned out to be positive prognostic factors.